

R E M A R K S

The specification was amended to insert a cross-reference to indicate that this application is the United States national phase application of International application PCT/JP2005/002884.

The amendments to the preamble of claim 1 are supported by original claims 9 to 13, pages 13 and 14 of the specification and the first two paragraphs on page 72 of the specification.

Claims 2 to 6, 8 and 18 were amended to be consistent with amended claim 1.

New claims 19 to 23 recite the compounds set forth in original claim 7.

New claim 24 combines the features of original claims 7 and 8.

New claims 25 to 29 recite the compounds set forth in original claim 7.

New claim 30 recites features of original claim 8.

New claims 31, 34 and 37 recite a feature supported on page 13, line 18 of the specification (warm-blooded animal). New claim 31 also recites features of original claims 9 to 14. New claim 34 also recites features of original claim 15. New claim 37 also recites a feature of original claim 17.

New claims 32, 34 and 38 recite a feature (human) that is supported in the specification on page 13, line 19.

New claims 33, 36 and 41 recite the features of original claim 18.

New claims 37, 39 and 40 are supported by the paragraph bridging pages 13 and 14 of the specification.

New claim 42 is the same as amended claim 1, but recites a warm-blooded animal (see page 13, line 18 of the specification), instead of a human.


Amended claim 1 and new claim 42 recite a method for suppressing the number of peripheral lymphocytes. Applicants have informed the undersigned that the suppression of the number of lymphocytes in the blood is a kind of mechanism by which the immune response may be lessened. US 2005/0043386A1 (which is the published application of copending related application Serial No. 10/889,657) discloses that the compounds disclosed therein have immunosuppressive effects. Therefore, the suppression of the number of lymphocytes in the blood may be an elucidation of the mechanism by which immunosuppression occurs.

The abstract was editorially revised.

Entry of the above amendments is respectfully requested.

If the Examiner has any comments, questions, objections or recommendations, the Examiner is invited to telephone the undersigned at the telephone number given below for prompt action.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Richard S. Barth". The signature is fluid and cursive, with a large, stylized "B" at the end.

Richard S. Barth
Reg. No. 28,180

Frishauf, Holtz, Goodman & Chick, P.C.
220 Fifth Avenue - 16th Floor
New York, New York 10001-7708
Tel. No. (212) 319-4900
Fax No. (212) 319-5101
E-mail Address: BARTH@FHGC-LAW.COM
RSB/ddf